Jump to content

Solifenacin: Difference between revisions

From Wikipedia, the free encyclopedia
Content deleted Content added
No edit summary
No edit summary
Line 27: Line 27:
'''Drug Interactions:''' ketoconazole
'''Drug Interactions:''' ketoconazole
strong CYP450 3A4 inhibitors
strong CYP450 3A4 inhibitors
QT interval-prolonging drugs. '''Vesicare is an extremely expensive drug, avoid purchasing this drug due to it's gigantic cost.'''
QT interval-prolonging drugs. {{drugbox
{{drugbox
| IUPAC_name = 1-azabicyclo[2.2.2]oct-8-yl (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate; butanedioic acid
| IUPAC_name = 1-azabicyclo[2.2.2]oct-8-yl (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate; butanedioic acid
| image = {{PAGENAME}}.png
| image = {{PAGENAME}}.png

Revision as of 16:57, 24 October 2006

Indication: Overactive bladder Pharmacology: Antimuscarinic Usual Dose: Initial: 5 mg orally once a day Contraindications: Hypersensitivity to solifenacin Urinary retention, gastric retention, uncontrolled narrow-angle glaucoma Warnings: Caution in significant bladder outflow obstruction, decreased GI motility, in patients being treated for narrow-angle glaucoma, renal or hepatic impairment Do not give doses >5 mg if CrCl<30 mL/min or moderate hepatic impairment (Child-Pugh B) Not recommended in severe hepatic impairment (Child-Pugh C) Do not give doses >5 mg if concomitant strong CYP450 3A4 inhibitors Caution in congenital or acquired QT interval prolongation Advise patients about blurred vision, constipation, potential for heat prostration Patients should contact physician if they have severe abdominal pain or are constipated for >=3 days Lactating women should discontinue nursing or discontinue the drug Safety and effectiveness not established in pediatric patients Pregnancy Category: C Side Effects: dry mouth, nausea, vomiting, constipation (e.g. can't poop), dyspepsia urinary tract infection, influenza, pharyngitis dizziness blurred vision, dry eye urinary retention edema, fatigue depression cough hypertension Drug Interactions: ketoconazole strong CYP450 3A4 inhibitors

QT interval-prolonging drugs.

Solifenacin
Clinical data
ATC code
Pharmacokinetic data
Elimination half-life45 - 68 hours
Identifiers
  • 1-azabicyclo[2.2.2]oct-8-yl (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate; butanedioic acid
CAS Number
PubChem CID
DrugBank
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC27H32N2O6
Molar mass480.553 g/mol

Solifenacin (or Solifenacin succinate) is a urinary antispasmodic.